Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 76
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Title
Phase
Protocol IDs
Comparing Peripheral Blood Stem Cell Transplantation Versus Bone Marrow Transplantation in Individuals With Hematologic Cancers
Phase III
418
BMTCTN-0201, NCT00075816
Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
Phase III
SCT 0307
NCT00619879
Chemotherapy Followed by Allogeneic Stem Cell Transplantation in Treating Children With Hematologic Cancer
Phase II, Phase I
NCI-01-C-0125F
NCT00020592
Stem Cell Transplant for Hematologic Diseases and Renal Cell Cancer
Phase II, Phase I
H8713
NCT00058825
Pentostatin and Donor White Blood Cells in Preventing Graft Rejection in Cancer Patients Who Have Undergone Donor Stem Cell Transplantation
Phase II, Phase I
FHCRC-1825.00
SUPERGEN-FHCRC-1825.00, NCT00096161
Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
Phase II, Phase I
9911M24961
MT1999-20, NCT00167219
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
Phase II, Phase I
MSKCC-06125
NCT00423514
Study of Pralatrexate and Gemcitabine With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Lymphoproliferative Malignancies
Phase II, Phase I
PDX-009
NCT00481871
Phase I, Open-Label, Dose-Escalation, Safety and Pharmacokinetics (PK) Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)
Phase II, Phase I
D2782C00007
NCT00486265
Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease
Phase II, Phase I
BCM-H-19386
BCM-FAB, H 19386, NCT00625144
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute